Nightingale Health Oyj Class B
1.25
EUR
+0.04
(+2.89%)
ISIN
FI4000490875
Return %
Stock
S&P 500
1Y
-44.67
14.20
3Y
19.71
81.12
5Y
- -
68.34
Capital Structure
EUR
•
in mil. unless spec.Working Capital
EUR
•
in mil. unless spec.Growth Rates
EUR
•
in mil. unless spec.Semi-annual Revenue
EUR
•
in mil. unless spec.Semi-annual Earnings Per Share
EUR
•
in mil. unless spec.Semi-annual Dividends Per Share
EUR
•
in mil. unless spec.Company Description
- CEO
- Teemu Pentti Suna
- Full Time Employees
- 101
- Sector
- Commercial services
- Industry
- Miscellaneous commercial services
- Address
- Helsinki Finland
- IPO Date
- Mar 19, 2021
- Website
- nightingalehealth.com
- Similar Companies
- Business
- Nightingale Health Oyj is a Finland-based health technology company that provides preventative healthcare solutions, clinical diagnostics, and blood-based biomarker analysis platforms. Founded in 2013 and headquartered in Helsinki, Finland, the company operates within the health technology and biotechnology sectors, with its Class B shares publicly traded on the Nasdaq Helsinki under the ticker symbol HEALTH. The company offers a comprehensive proprietary technology platform centered on high-throughput Nuclear Magnetic Resonance (NMR) spectroscopy and advanced machine learning algorithms to measure and quantify over 250 metabolic biomarkers from a single blood sample. Its core product and service portfolio comprises: the Nightingale Health Check, a preventative health risk assessment service that delivers 10-year risk predictions for chronic diseases such as cardiovascular disease, type 2 diabetes, kidney fibrosis, and liver disorders; the Livit by Nightingale Health consumer health platform, a direct-to-consumer and corporate wellness subscription service delivered via a mobile application that provides personalized biological health metrics, including Healthy Years, Heart Age, Diabetes Resistance, Mind Resilience, and Immune Resilience; the Nightingale Remote Health Check, an end-to-end at-home testing service utilizing proprietary dried blood spot collection kits; the Velvet blood collection device, an automated micro-sampling system for precise, painless capillary blood self-collection; and specialized Research and Multiomics Services, providing high-volume metabolomic profiling, biobank sample characterization, and clinical cohort analytics for pharmaceutical companies, universities, and research institutions globally. Nightingale Health serves healthcare providers, occupational health service organizations, public health authorities, research institutions, and individual consumers across Europe, North America, Japan, and the Middle East, maintaining laboratory facilities and operating subsidiaries in Finland, the United Kingdom, Japan, and the United States. In recent strategic developments, the company has accelerated international commercialization and deepened its diagnostics integration across public and private healthcare sectors. Nightingale Health completed the strategic acquisition of Japanese preventative health company Welltus Inc. to strengthen its presence in Asia and acquired the full intellectual property rights to the Velvet blood collection device to secure its supply chain for remote sampling. On the commercial front, the company executed major partnership agreements, including an expanded nationwide deployment with Finland's largest healthcare provider Terveystalo; a commercial rollout agreement with Boston Heart Diagnostics in the United States following a successful pilot phase; a regional multi-phase expansion agreement with Enigma Genomics to deliver remote health check solutions across Saudi Arabia and the MENA region; and an integration agreement with the South Savo Wellbeing Services County to incorporate multiomics-based disease prevention into Finnish public primary care. Additionally, the company secured major biomarker analysis agreements with prominent global research initiatives, including the Kaiser Foundation Health Plan, the Italian Moli-sani cohort study, Phenome Health, and Aalborg University.